<sec>
<b>Objectives</b>
<p>To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).</p></sec>
<sec>
<b>Methods</b>
<p>4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).</p></sec>
<sec>
<b>Results</b>
<p>Of the global sample of 55 patients included in this study; SOF + DCV (<italic>n</italic> = 10); SOF + DCV + RBV (<italic>n</italic> = 29); SOF + SMV (<italic>n</italic> = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups: SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6).</p></sec>
<sec>
<b>Conclusion</b>
<p>Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.</p></sec>
Citations
Citations to this article as recorded by
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection Olav Dalgard, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward J. Gane, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara A. Haber, Heather Platt, Amy Journal of Addictive Diseases.2023; 41(3): 213. CrossRef
Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus Evy Yunihastuti, Fhadilla Amelia, Arini Ika Hapsari, Bramantya Wicaksana, Veritea Natali, Alvina Widhani, Andri Sanityoso Sulaiman, Teguh Harjono Karjadi Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free Raíssa Neves Fagundes, Lincoln Eduardo Villela Vieira de Castro Ferreira, Fábio Heleno de Lima Pace, Yury E. Khudyakov PLOS ONE.2020; 15(8): e0237005. CrossRef
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination Juan Li, Dong-Bo Wu, Wei Jiang, Xue-Bin Chen, Gui-Bao Xiao, Yong-Hong Wang, Meng-Lan Wang, Ya-Chao Tao, En-Qiang Chen Medicine.2020; 99(43): e22726. CrossRef